Research

Patients with extensive-stage small cell lung cancer who received a combination of two immunotherapies as first-line maintenance therapy had a median overall survival more than eight months longer than those who received one immunotherapy alone, according to a study published…

Older cancer survivors who were more physically active after diagnosis had lower healthcare costs than those who were less active, according to a study published Oct. 21 in Cancer. Researchers from the American Cancer Society analyzed Medicare claims and survey…

More than three-quarters of U.S. counties had no active triple-negative breast cancer treatment trials, according to a study published Sept. 28 in Breast Cancer Research and Treatment. Researchers from Houston-based University of Texas MD Anderson Cancer Center analyzed active phase…

Commercial insurers initially rejected 84% of new specialty oral blood cancer drug prescriptions, while Medicare plans rejected 64.9%, according to a study published Sept. 30 in the Journal of Clinical Oncology. Researchers from Philadelphia-based University of Pennsylvania analyzed prescription and…

Two recent studies have uncovered disparities in cervical cancer screening and vaccination rates, highlighting the uneven uptake of prevention strategies across the U.S. In one study, published Oct. 16 in JAMA Network Open, researchers from the University of Texas Health…

For decades, researchers have sought to develop vaccines to treat cancer, but progress has been limited by the complexity of the disease, the diversity of cancer types and biological differences among individual patients. Now, a personalized cancer vaccine has succeeded…

Rochester, Minn.-based Mayo Clinic will evaluate a new GE HealthCare SPECT/CT imaging system designed to support theranostics. Mayo Clinic is one of five institutions worldwide participating in GE HealthCare’s clinical evaluation program for the StarGuide GX system, according to an…

Nearly 60% of the time, older breast cancer survivors with high frailty-related needs did not receive Medicare home healthcare, according to a study published Oct. 19 in JNCI: Journal of the National Cancer Institute. Researchers from the University of Maryland…

As healthcare leaders celebrate the FDA’s approval of daraxonrasib — a pancreatic cancer drug that nearly doubled survival in clinical trials — two harsh realities remain: most pancreatic cancer patients are still diagnosed at a late stage, and those treated…

Medical oncologists who received drug industry payments were more likely to prescribe treatments tied to those payments, even when the treatments were not guideline-preferred, according to a study published Sept. 15 in the Journal of Clinical Oncology. Led by researchers…